Recently, several studies have examined the levels of exosomal PD-L1 in the blood of cancer patients, and suggest the potential use of exosomal PD-L1 as an indicator or predictor of patient response to ICB-based therapies15,16,21,50–52. Here, CD274 is linked to cancer.